Human iPSC-derived Cortical Neurons

  • Specification
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-00843L
Description
Human iPSC-derived Cortical Neurons are derived from human dermal cells, using integration-free induced pluripotent stem cell (iPSC) lines under a fully defined proprietary induction and maturation conditions. Human iPSC-derived Cortical Neurons are branched structures when plated as a monolayer in culture and express biomarkers such as beta-3-Tuj, GAD65/67, VGLUT1/2, and Map2. Human iPSC-derived Cortical Neurons can be used under maturation conditions, co-culture conditions (with astrocytes), and short-term functional characterization studies.
Species
Human
Culture Properties
Adherent
Application
For Research Use Only
Shipping
Dry Ice
Quality Control
Sterility, Safety, (BioSafety Level 2), HIV/viruses, bacteria, fungi: negative. Cell viability post-thawing >90%
Storage and Shipping
Remove cryovials (dry ice packaging) and place the vial into liquid nitrogen for storage. Alternatively, thaw and use the cells immediately.
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Circulating neuron-derived cfDNA for blood-based detection of Alzheimer’s and other neurodegenerative conditions

Frontiers in Neurology | DOI | Paper |

Background

This proof-of-concept study demonstrates that native nanopore sequencing can generate a human brain methylation atlas and classify neuron-derived cfDNA from blood plasma. Using six primary neural cell types, the authors developed cell-type-specific classifiers and applied them to 137 plasma samples from Alzheimer’s disease, Parkinson’s disease, ALS, mild cognitive impairment, and controls. Elevated cortical neuron-like cfDNA occurred in AD/MCI, dopaminergic neuron-like cfDNA in PD, and spinal motor neuron-like cfDNA in ALS. Multivariate integration improved diagnostic separation (AUC >0.85). Native sequencing avoids bisulfite/PCR bias, supporting liquid biopsy for neurodegenerative disease.

Key Findings

The study generated a methylation reference atlas from six primary human neural cell populations—cortical neurons, dopaminergic neurons, spinal motor neurons, astrocytes, Schwann cells, and microglia—using whole-genome native nanopore sequencing. This enabled cell-type-specific cfDNA classifiers with high analytical accuracy in in silico dilution series (R² up to 0.998). In 137 plasma samples, classifier signals aligned with selectively vulnerable neurons: cortical neuron-like cfDNA was elevated in AD and progressive MCI (22.27% vs 7.42% controls), dopaminergic neuron-like cfDNA in PD (45.01% vs 10.94%), and spinal motor neuron-like cfDNA in ALS (7.11% vs 2.48%). Multivariate integration of neuronal signatures improved disease discrimination, achieving AUC >0.85 in multi-disease comparisons. iPSC-derived neuron classifiers failed to replicate disease signals, highlighting the value of primary-cell references. The work supports native cfDNA nanopore methylation sequencing as a flexible platform for cell-of-origin analysis in neurodegeneration.

Contribution

Creative Bioarray supplied purified human neural cell populations, including primary and iPSC-derived cortical and dopaminergic neurons and glial cells, used to generate the whole-genome nanopore methylation reference atlas. These reference methylomes enabled development of cell-type-specific cfDNA classifiers for neurodegeneration analysis.

Neuron-like cfDNA classification aligns with selective neurodegeneration across diseases.
Fig. 1. Neuron-like cfDNA classification aligns with selective neurodegeneration across diseases.

Circulating Cell-Free DNA Methylation Profiles Enable Disease-Specific Detection of Alzheimer’s, Parkinson’s, and ALS from Blood

medRxiv | DOI | Paper |

Background

This study presents a blood-based cfDNA methylation platform for noninvasive detection of neurodegenerative diseases. Whole-genome nanopore methylation atlases of six primary human neural cell types were used to train classifiers assigning cfDNA to neuronal or glial origins. Classifiers were validated in silico and applied to 219 plasma samples from Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and controls. Disease-specific cfDNA elevations were detected, with predictive AUCs >0.99. In mild cognitive impairment, cortical cfDNA elevation identified individuals who later progressed to Alzheimer’s disease. A multivariate model improved accuracy, supporting cfDNA methylation profiling as a scalable framework.

Key Findings

The authors developed a cfDNA methylation platform capable of resolving cell-of-origin signals in blood. A whole-genome nanopore methylation atlas covering cortical, dopaminergic, and spinal motor neurons, astrocytes, Schwann cells, and microglia enabled classifiers that assign cfDNA to neural cell types. In 219 plasma samples, cortical cfDNA was elevated in Alzheimer’s disease, dopaminergic cfDNA in Parkinson’s disease, and spinal motor neuron cfDNA in amyotrophic lateral sclerosis, achieving AUCs >0.99. Mild cognitive impairment cases that later converted to Alzheimer’s disease showed elevated cortical cfDNA. Multivariate modeling integrating multiple neuronal signals improved sensitivity, specificity, and accuracy. The study demonstrates that cfDNA methylation profiling can detect and differentiate neurodegenerative diseases noninvasively, with potential for early detection and monitoring.

Contribution

Creative Bioarray offers purified human neurons and glial cells, including primary and iPSC-derived cortical neurons (CSC-C1514; CSC-00834L), primary and iPSC-dopaminergic neurons (CSC-C30012; CSC-00842L), as well as human astrocytes (CSC-7836W), human Schwann cells (CSC-7836W) and human microglia (CSC-C1528), which are used to construct a whole-genome nanopore methylation reference map and train a classifier for cell source classification from cfDNA.

Whole-genome nanopore profiling identifies cell type-specific methylation signatures
Fig. 2. Whole-genome nanopore profiling identifies cell type-specific methylation signatures

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products